REGENT PACIFIC (00575.HK): Submitted a new drug application for Senstend to the National Medical Products Administration of China.

Gelonghui, on March 25, announced that REGENT PACIFIC (00575.HK) stated that its commercial strategic partner Jiangsu Wanbang Biochemical Pharmaceutical Group Co., Ltd. ("Jiangsu Wanbang Pharma", a wholly-owned subsidiary of Shanghai FOSUN PHARMA (Group) Co., Ltd.) has received confirmation from the National Medical Products Administration on March 24, 2025, that the new drug application registration file submitted on December 17, 2024, has passed the first phase of the review process by the National Medical Products Administration, and the file meets all regulatory requirements. The National Medical Products Administration will now continue with the next phase of the review process.

Gelonghui FinanceMar 25 17:39

Regent Pacific Group to Approve Year-End Results and Consider Dividend

TipRanksMar 17 17:22

REGENT PACIFIC (00575.HK) will hold a Board of Directors meeting on March 27 to approve the annual results.

Gelonghui, March 17 - REGENT PACIFIC (00575.HK) announced that the Board of Directors will hold a meeting on March 27, 2025, to approve the announcement of the annual results for the year ending December 31, 2024, and to consider the proposal for the final dividend distribution (if any).

Gelonghui FinanceMar 17 16:53

REGENT PACIFIC: Date of Board Meeting

HKEXMar 17 16:43 · Announcements

All the way up! The Innovative Drugs Sector in Hong Kong stocks surged collectively, with multiple stocks doubling this year. Who is reshaping the valuation?

The rise in the Hong Kong stock market's Innovative Drugs Sector continues. Market analysts point out that this wave of Innovative Drugs momentum benefits from a combination of factors including market sentiment, policy, and the realization of the companies' own commercial value.

Securities TimesMar 13 09:50

Announcement Highlights | SINGAMAS CONT's profit in 2024 increased by more than 50% year-on-year; AIA repurchased over 0.3 billion HKD in a single day.

REGENT PACIFIC issued a profit warning, expecting an annual loss attributable to Shareholders of approximately 4 million to about 5 million USD, a significant decrease in losses year-on-year; COSCO Shipping Holdings spent 54.4382 million HKD to buy back 4.8 million shares, with the buyback price ranging from 11.24 to 11.44 HKD per share.

cls.cnFeb 5 07:58